ARCH Venture Partners, a Chicago-based investment firm that provides seed / early stage venture capital for technology firms, has raised $1.46 billion funding round.
The firm is focusing to finance new tech development platforms who are participating in the races to develop vaccines and therapies to treat COVID-19.
ARCH Ventures Partner has added two new funds in its long line of investment, ARCH Venture Fund X and ARCH Venture Fund X Overage, which are dedicated to invest in early-stage biotechnology companies. Both the new funds are being led by Managing directors includingRobert Nelsen, Kristina Burow, Keith Crandell, Steve Gillis, Paul Thurk, and Mark McDonnell.
Robert Nelsen, the Co-founder and Managing Director of ARCH states, “ARCH has always been driven to inv-est in great science to impact human health. There isn’t a better illustration of our principles than our all-in battle against COVID-19.” He adds, “The healthcare revolution will be accelerated by the changes that are happening now and we are excited to continue to invest aggressively in risk takers doing truly transformational science.”
ARCH has previously invested in Alnylam Pharmaceuticals, Brii Biosciences, Sana Biotechnology, Vir Biotechnology, and VBI Vaccines which are all working on COVID-19 therapeutics. ARCH has also invested in Quanterix which is currently working on a project to develop a technology to support clinical trial development and clinical testing.
Kristina Burow states, “Our companies bring cutting-edge science, tools and talent to bear in developing medicines for a wide range of diseases and conditions faced by millions. With these two new funds, we are continuing that work with urgency and a deep sense of purpose. We invest at all levels, whether it’s fifty thousand dollars or hundreds of millions, so that each company and each technology has the best chance to advance and change the landscape.”
For More Information about Blogs and News: Click Here